KR930009607A - 증식성 질환의 치료를 위한 다이피리다몰 - Google Patents
증식성 질환의 치료를 위한 다이피리다몰 Download PDFInfo
- Publication number
- KR930009607A KR930009607A KR1019920021672A KR920021672A KR930009607A KR 930009607 A KR930009607 A KR 930009607A KR 1019920021672 A KR1019920021672 A KR 1019920021672A KR 920021672 A KR920021672 A KR 920021672A KR 930009607 A KR930009607 A KR 930009607A
- Authority
- KR
- South Korea
- Prior art keywords
- dipyridamole
- administration
- use according
- cell proliferation
- treatment
- Prior art date
Links
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title claims abstract 7
- 229960002768 dipyridamole Drugs 0.000 title claims abstract 7
- 230000002062 proliferating effect Effects 0.000 title claims abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 claims abstract 3
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 230000035755 proliferation Effects 0.000 claims abstract 2
- 238000011200 topical administration Methods 0.000 claims abstract 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
억제량의 다이피리다몰을 국소 투여하는 것을 포함하는, 포유동물에서 세포 증식을 억제하는 방법이 개시된다. 세포증식의 억제를 혈관성 재발협착증, 공피증, 건선 및 류마티스관절염 등과 같은 증식성 질환의 치료에 유용하다. 본 발명은 국소 투여 카테터, 부위 특이적 담체, 이식편, 직접 주사 또는 직접 적용등의 다양한 투여기법에 의해 증식부위에 다이피리다몰을 국소 투여하는 방법이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 증식 부위에 직접 다이피리다몰을 투여함으로써 세포 증식을 비-전신적 방법으로 치료하기 위한 다이피리다몰의 용도.
- 증식성 혈관 평활근 세포에 직접 다이피리다몰을 투여함으로써 혈관 평활근 세포 증식을 비-전신적 방법으로 치료하기 위한 다이피리다몰의 용도.
- 제2항에 있어서, 국소 투여용 카테터를 사용하여 투여하는 용도.
- 제2항에 있어서, 부위 특이적 담체를 사용하여 투여하는 용도.
- 제2항에 있어서, 이식편을 사용하여 투여하는 용도.
- 제2항에 있어서, 막고정 링커를 사용하여 투여하는 용도.
- 제2항에 있어서, 직접 주사에 의해 투여하는 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/795,434 | 1991-11-21 | ||
US07/795,434 US5270047A (en) | 1991-11-21 | 1991-11-21 | Local delivery of dipyridamole for the treatment of proliferative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930009607A true KR930009607A (ko) | 1993-06-21 |
Family
ID=25165502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920021672A KR930009607A (ko) | 1991-11-21 | 1992-11-18 | 증식성 질환의 치료를 위한 다이피리다몰 |
Country Status (12)
Country | Link |
---|---|
US (2) | US5270047A (ko) |
EP (1) | EP0543653A1 (ko) |
JP (1) | JPH05201862A (ko) |
KR (1) | KR930009607A (ko) |
AU (1) | AU661067B2 (ko) |
CA (1) | CA2083223A1 (ko) |
HU (1) | HU212422B (ko) |
MX (1) | MX9206610A (ko) |
NO (1) | NO924461L (ko) |
RU (1) | RU2084224C1 (ko) |
TW (1) | TW252917B (ko) |
ZA (1) | ZA928832B (ko) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5770609A (en) * | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6395494B1 (en) | 1993-05-13 | 2002-05-28 | Neorx Corporation | Method to determine TGF-β |
US6306421B1 (en) | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6663881B2 (en) * | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) * | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1994016706A1 (en) * | 1993-01-28 | 1994-08-04 | Neorx Corporation | Therapeutic inhibitors of vascular smooth muscle cells |
JPH08510451A (ja) * | 1993-05-13 | 1996-11-05 | ネオルックス コーポレイション | 異常増殖性平滑筋細胞に関連した病因の予防及び治療 |
DE69435342D1 (de) * | 1993-07-19 | 2011-05-05 | Angiotech Pharm Inc | Anti-Angiogene Mittel und Verfahren zu deren Verwendung |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5521191A (en) * | 1994-10-17 | 1996-05-28 | Washington University | Method for treatment of arterial stenosis |
US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US6558798B2 (en) | 1995-02-22 | 2003-05-06 | Scimed Life Systems, Inc. | Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity |
US7896914B2 (en) * | 1995-06-07 | 2011-03-01 | Cook Incorporated | Coated implantable medical device |
US7846202B2 (en) | 1995-06-07 | 2010-12-07 | Cook Incorporated | Coated implantable medical device |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US7867275B2 (en) * | 1995-06-07 | 2011-01-11 | Cook Incorporated | Coated implantable medical device method |
US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
AU6277396A (en) | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US7550005B2 (en) * | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
US20070203520A1 (en) * | 1995-06-07 | 2007-08-30 | Dennis Griffin | Endovascular filter |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5951586A (en) * | 1996-05-15 | 1999-09-14 | Medtronic, Inc. | Intraluminal stent |
DK0914102T3 (da) | 1996-05-24 | 2006-01-09 | Angiotech Pharm Inc | Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler |
US20060052757A1 (en) * | 1996-06-04 | 2006-03-09 | Vance Products Incorporated, D/B/A Cook Urological Incorporated | Implantable medical device with analgesic or anesthetic |
US20060030826A1 (en) * | 1996-06-04 | 2006-02-09 | Vance Products Incorporated,d/b/a Cook Urological Incorporated | Implantable medical device with anti-neoplastic drug |
US20060025726A1 (en) * | 1996-06-04 | 2006-02-02 | Vance Products Incorporated, D/B/A Cook Urological Incorporated | Implantable medical device with pharmacologically active layer |
US6530951B1 (en) | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6569688B2 (en) | 1997-08-26 | 2003-05-27 | Technion Research & Development Foundation Ltd. | Intravascular apparatus method |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US20040254635A1 (en) * | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US7208010B2 (en) * | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
JP4898991B2 (ja) | 1998-08-20 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | 被覆付植込式医療装置 |
US6168619B1 (en) * | 1998-10-16 | 2001-01-02 | Quanam Medical Corporation | Intravascular stent having a coaxial polymer member and end sleeves |
US6293967B1 (en) | 1998-10-29 | 2001-09-25 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6156373A (en) | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6290673B1 (en) | 1999-05-20 | 2001-09-18 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
ATE460951T1 (de) * | 2000-01-25 | 2010-04-15 | Edwards Lifesciences Corp | Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie |
US6764507B2 (en) | 2000-10-16 | 2004-07-20 | Conor Medsystems, Inc. | Expandable medical device with improved spatial distribution |
ES2243556T3 (es) | 2000-10-16 | 2005-12-01 | Conor Medsystems, Inc. | Dispositivo medico expandible para proporcionar un agente beneficioso. |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US20040073294A1 (en) * | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US6964680B2 (en) * | 2001-02-05 | 2005-11-15 | Conor Medsystems, Inc. | Expandable medical device with tapered hinge |
DE10115740A1 (de) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
US7064130B2 (en) | 2001-04-20 | 2006-06-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders |
DE10119680A1 (de) * | 2001-04-20 | 2002-11-14 | Boehringer Ingelheim Pharma | Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation |
US7842083B2 (en) | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
EP1448205B1 (en) | 2001-10-05 | 2011-03-23 | Zalicus Inc. | Combinations for the treatment of immunoinflammatory disorders |
US20030077310A1 (en) * | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
US20030083614A1 (en) * | 2001-10-30 | 2003-05-01 | Boehringer Ingelheim Pharma Kg | Controlled release endoprosthetic device |
EP1308179A1 (en) * | 2001-10-30 | 2003-05-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Improved endoprosthetic device |
TW200301135A (en) * | 2001-12-27 | 2003-07-01 | Otsuka Maryland Res Inst Inc | Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
MXPA04006875A (es) * | 2002-01-18 | 2004-12-06 | Control Delivery Sys Inc | Sistema de gel polimerico para suministro controlado de cofarmacos. |
US10441747B2 (en) | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
AU2003205315A1 (en) * | 2002-01-22 | 2003-09-02 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
US7744584B2 (en) | 2002-01-22 | 2010-06-29 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
US7097850B2 (en) | 2002-06-18 | 2006-08-29 | Surmodics, Inc. | Bioactive agent release coating and controlled humidity method |
EP1521603B1 (en) * | 2002-07-12 | 2011-01-19 | Cook Incorporated | Coated medical device |
US20040127976A1 (en) * | 2002-09-20 | 2004-07-01 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
DE10244847A1 (de) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
US20040162542A1 (en) * | 2002-12-03 | 2004-08-19 | Endobionics, Inc. | Methods and systems for treating the vasculature with estrogens |
CN1747734A (zh) * | 2003-02-07 | 2006-03-15 | 贝林格尔·英格海姆国际有限公司 | 潘生丁或单哌潘生丁在治疗和预防mmp-9-依赖性疾病中的用途 |
WO2004087214A1 (en) | 2003-03-28 | 2004-10-14 | Conor Medsystems, Inc. | Implantable medical device with beneficial agent concentration gradient |
US7169179B2 (en) * | 2003-06-05 | 2007-01-30 | Conor Medsystems, Inc. | Drug delivery device and method for bi-directional drug delivery |
US7785653B2 (en) * | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20050112199A1 (en) * | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2007139753A2 (en) * | 2006-05-22 | 2007-12-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels |
WO2009038708A1 (en) * | 2007-09-19 | 2009-03-26 | Combinatorx, Incorporated | Therapeutic regimens for the treatment of immunoinflammatory disorders |
CN101938996A (zh) * | 2007-12-17 | 2011-01-05 | 康宾纳特克斯公司 | 用于治疗免疫炎症性紊乱的治疗方案 |
CA3035774A1 (en) | 2016-09-22 | 2018-03-29 | Mercator Medsystems, Inc. | Treatment of restenosis using temsirolimus |
CN110996687A (zh) | 2017-05-26 | 2020-04-10 | 墨卡托医疗系统公司 | 用于治疗再狭窄的联合疗法 |
CN110382019B (zh) | 2018-03-14 | 2020-08-25 | 墨卡托医疗系统公司 | 用于局部药物递送的医疗器械和医疗方法 |
WO2021077070A1 (en) * | 2019-10-18 | 2021-04-22 | Yale University | Compositions and methods for inhibition of cell-penetrating antibodies |
CN113244395B (zh) * | 2020-02-10 | 2024-07-23 | 广州市妇女儿童医疗中心 | 纤维化疾病机制及其治疗药物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
CA1208516A (en) * | 1982-04-02 | 1986-07-29 | Harvey Wolinsky | Methods and apparatus for relieving arterial constrictions |
US4824436A (en) * | 1985-04-09 | 1989-04-25 | Harvey Wolinsky | Method for the prevention of restenosis |
AU4191989A (en) * | 1988-08-24 | 1990-03-23 | Marvin J. Slepian | Biodegradable polymeric endoluminal sealing |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
DE69023362T2 (de) * | 1989-01-31 | 1996-04-04 | Bard Inc C R | Katheter und Methode zur lokal angewandten Medikation der Wand eines Blutgefässes oder eines anderen Körperlumens. |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5171217A (en) * | 1991-02-28 | 1992-12-15 | Indiana University Foundation | Method for delivery of smooth muscle cell inhibitors |
-
1991
- 1991-11-21 US US07/795,434 patent/US5270047A/en not_active Expired - Fee Related
-
1992
- 1992-11-16 RU RU9292004406A patent/RU2084224C1/ru active
- 1992-11-16 ZA ZA928832A patent/ZA928832B/xx unknown
- 1992-11-17 MX MX9206610A patent/MX9206610A/es not_active Application Discontinuation
- 1992-11-18 AU AU28454/92A patent/AU661067B2/en not_active Ceased
- 1992-11-18 TW TW081109231A patent/TW252917B/zh active
- 1992-11-18 CA CA002083223A patent/CA2083223A1/en not_active Abandoned
- 1992-11-18 KR KR1019920021672A patent/KR930009607A/ko not_active Application Discontinuation
- 1992-11-18 JP JP4308615A patent/JPH05201862A/ja not_active Withdrawn
- 1992-11-19 EP EP92310577A patent/EP0543653A1/en not_active Withdrawn
- 1992-11-19 NO NO92924461A patent/NO924461L/no unknown
- 1992-11-19 HU HU9203626A patent/HU212422B/hu not_active IP Right Cessation
-
1993
- 1993-02-09 US US08/015,486 patent/US5314688A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
HU9203626D0 (en) | 1993-01-28 |
US5314688A (en) | 1994-05-24 |
HU212422B (en) | 1996-06-28 |
HUT70034A (en) | 1995-09-28 |
JPH05201862A (ja) | 1993-08-10 |
MX9206610A (es) | 1993-05-01 |
ZA928832B (en) | 1994-05-16 |
AU2845492A (en) | 1993-05-27 |
AU661067B2 (en) | 1995-07-13 |
NO924461D0 (no) | 1992-11-19 |
EP0543653A1 (en) | 1993-05-26 |
RU2084224C1 (ru) | 1997-07-20 |
CA2083223A1 (en) | 1993-05-22 |
TW252917B (ko) | 1995-08-01 |
NO924461L (no) | 1993-05-24 |
US5270047A (en) | 1993-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930009607A (ko) | 증식성 질환의 치료를 위한 다이피리다몰 | |
RU92004406A (ru) | Дипиридамол для лечения пролиферативных болезней | |
FI943805A (fi) | Substituoituja adeniinijohdannaisten käyttö multippeliskleroosin hoitoon | |
IS4073A (is) | Nýtt fjölvirknislyf gegn aukningu mótstöðu | |
DE69833942D1 (de) | Verwendung einer neurotoxintherapie zur behandlung von prostata erkrankungen | |
DE69725293D1 (de) | N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität | |
ATE221881T1 (de) | Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat | |
ATE202140T1 (de) | Hemmung der neovaskulasierung durch vegf- spezifische oligonukleotide | |
ATE407573T1 (de) | Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion | |
NO991685D0 (no) | Anvendelse av 1-benzyl-3-(substituert hetaryl)-kondenserte pyrazolderivater for behandling av spesielle sykdommer i hjerte-kretsl°psystemet og sentralnervesystemet | |
HN1998000143A (es) | Tetrahidronaftalenos substituidos y compuestos analogos. | |
ES2147780T3 (es) | Compuestos sinteticos afines al extracto de corteza de roble, y procedimiento para utilizar los mismos. | |
DE69526853D1 (de) | Hemmung der fortpflanzung von arterienglattmuskelzellen | |
RU94020410A (ru) | Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений | |
DE69201660D1 (de) | Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma. | |
ATE526944T1 (de) | Selbstbräunungszusammensetzungen die cholesterolsulfat und dha enthalten | |
ES2061811T3 (es) | Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera. | |
ES2171419T3 (es) | Uso de los inhibidores del citocromo p450 para inhibir el metabolismo del nitrogeno sustituido acridina. | |
PT768886E (pt) | Efeitos de revestimento endotelial e tratamento de desordens vasospasticas | |
MX9304626A (es) | Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares. | |
DE59900286D1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
GEP20012511B (en) | Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis | |
ATE245991T1 (de) | Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin | |
DE69218200D1 (de) | Behandlung von leberkrebs | |
LV11593A (lv) | Dimetikona pielietojums aizcietejumu arstesana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |